---
title: "Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation"
date: 2026-01-01
doi: https://doi.org/10.1002/trc2.70193
author:
  - name: Reina Tonegawa-Kuji
    affiliations:
      - ref: ccf
  - name: Ehud Karavani
    affiliations:
      - ref: ibmrisrl
  - name: Michael M. Danziger
    affiliations:
      - ref: ibmrisrl
  - name: Pengyue Zhang
    affiliations:
      - name: "Indiana University"
        country: United States
  - name: Yuan Hou
    affiliations:
      - ref: ccf
  - name: Yadi Zhou
    affiliations:
      - ref: ccf
  - name: Marina Bykova
    affiliations:
      - ref: ccf
  - name: Andrew A. Pieper
    affiliations:
      - ref: ccf
  - name: Michal Rosen-Zvi
    affiliations:
      - ref: ibmrisrl
  - name: Jeffrey Cummings
    affiliations:
      - name: "University of Nevada Las Vegas"
        country: United States
  - name: Feixiong Cheng
    affiliations:
      - ref: ccf
affiliations: 
  - id: ibmrisrl
    name: IBM Research
    # organization: IBM Research
    country: Israel
    department: Causal Machine Learning for Healthcare and Life Sciences
  - id: ccf
    name: Cleveland Clinic
    country: United States
categories:
  - causal inference
  - healthcare
# keywords: 
publication: "Alzheimer's & Dementia "
journal: 
  title: "Alzheimer's & Dementia "
pdf: https://alz-journals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/trc2.70193?download=true
abstract: >
  INTRODUCTION
  Repurposing Food and Drug Administration (FDA)-approved drugs could accelerate treatment development for Alzheimer's disease (AD).
  METHODS
  Using the MarketScan claims database (2011 to 2020), we applied a trial emulation approach in two base cohorts: (1) individuals with mild cognitive impairment (MCI cohort) and (2) individuals aged â‰¥70 years (over-70 cohort). We evaluated drugs represented in clinical trials for AD, comparing them with same-class or active comparators. Covariate-adjusted hazard ratios (HRs) were estimated using inverse-probability-weighted Cox models.
  RESULTS
  A total of 6 out of 38 (16%) drugs in the MCI cohort and 10 out of 53 (19%) drugs in the over-70 cohort were associated with a lower AD incidence versus same-class comparators. Active comparator analyses indicated that bupropion (vs escitalopram; HR 0.57, 95% confidence interval [CI] [0.49, 0.66]), trazodone (vs sertraline; HR 0.82, 95% CI [0.74, 0.91]), venlafaxine (vs escitalopram; 0.72, 95% CI [0.62, 0.84]), and zolpidem (vs lorazepam; HR 0.69, 95% CI [0.56, 0.85]) were associated with a lower AD incidence in the MCI cohort; these four plus liraglutide were associated with a lower incidence of AD dementia in the over-70 cohort (vs metformin; HR 0.74, 95% CI [0.59, 0.93]).
  DISCUSSION
  This is the first comprehensive set of trial emulations for FDA-approved drugs that are represented in AD trials. Findings may inform future trial designs.
description: >
  High-throughput target-trial emulations to evaluate potential drug candidates for delaying Alzheimer's onset.
---

![](figure1.jpg)

:::{.column-page}
![](figure2.png)
:::



## Citation
```bibtex
@article{kuji2026critical,
  author={Tonegawa-Kuji, Reina and Karavani, Ehud and Danziger, Michael and Zhang, Pengyue and Hou, Yuan and Zhou, Yadi and Bykova, Marina and Pieper, Andrew A. and Rosen-Zvi, Michal and Cummings, Jeffrey and Cheng, Feixiong},
  title={Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation},
  journal={Alzheimer's \& Dementia: Translational Research \& Clinical Interventions},
  doi={https://doi.org/10.1002/trc2.70193},
  year={2026}
}
```

